Vaccines and biologics against infectious diseases - T32 - VBAID project summary/abstract this application proposes the establishment of the vaccines and biologics against infectious diseases…
Active Cooperative Agreement Awarded
- Award ID
- T32AI187320
- Recipient
-
Duke University UEI TP7EK8DZV6N5
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $253,970
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 4% complete
- Place of performance
- Durham, NC 27705, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded Duke University Cooperative Agreement T32AI187320, with $253,970 obligated, on September 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award establishes the Vaccines and Biologics Against Infectious Diseases (VBAID) training program at the Duke Human Vaccine Institute within the Duke University School of Medicine. Postdoctoral trainees receive exposure to basic and translational research on pathogens at the cellular and molecular levels, and to pathogenesis studies that inform the design, development, and testing of candidate vaccines and biologics in preclinical animal studies and human clinical trials. Trainees engage in the program for up to three-year appointments and choose one of three tracks: host immunity to pathogens for antibody discovery and to inform vaccine design; vaccine development against viral infections; or maternal/pediatric immunity. The place of performance is Durham, North Carolina 27705. The period of performance runs from the September 9, 2026 award date to an ultimate completion date of August 31, 2031. The source identifies no sub-recipients for this award.
Description
Vaccines and biologics against infectious diseases - T32 - VBAID project summary/abstract this application proposes the establishment of the vaccines and biologics against infectious diseases (VBAID) training program in the duke human vaccine institute (DHVI), home to an outstanding group of faculty mentors working on a myriad of infectious diseases. The VBAID T32 program will provide a unique training program for postdoctoral trainees at DHVI in duke university school of medicine where they will have exposure to basic and translational science research that includes understanding pathogens at the cellular and molecular levels, and pathogenesis studies that informs the design, development and testing of candidate vaccines and biologics against pathogens in preclinical animal studies and human clinical trials; all within the DHVI, thus providing an academic environment with many enrichment opportunities. The diverse portfolio of topics in infectious diseases research provides a wide range of opportunities for trainees to work with the scientists who comprise the VBAID faculty. Objectives and rationale. Our vision is to provide an innovative program in vaccines and biologics development built upon state-of-the art interdisciplinary training and technology for the next generation of scientists. Our training program will equip postdoctoral scientists to be at the forefront of designing solutions to emerging threats impacting public health. The DHVI and associated faculty members are at the forefront of developing solutions to combat the most challenging epidemics including HIV, emerging coronaviruses, influenza, tuberculosis, and flaviviruses, among others. Research training program. Trainees engage in the program for up to three-year appointments and choose a program track: I. Host immunity to pathogens for antibody discovery and to inform vaccine design; II. Vaccine development against viral infections; and III. Maternal/pediatric immunity. Trainees can also select from one or more "enrichment opportunities": computational biology and bioinformatics, biostatistics and artificial intelligence, good manufacturing process and quality assurance, clinical trials and biocontainment research. Trainees must complete required training activities such as training in responsible conduct of research, training in human and animal research and data integrity. Additionally, through the well-established DHVI training and mentoring program (DTMP), trainees will have exposure to courses including but not limited to scientific writing, grant development, weekly journal clubs, state of the art technology training, statistics and informatics courses, research presentation skills and scientific communication to the general public. With this award, we anticipate training 3 post-doctoral PHD level researchers to successfully lead high impact research.
Quick answers
Who received award T32AI187320?
T32AI187320 was awarded to Duke University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 9, 2026.
How much is award T32AI187320 worth?
$253,970 has been obligated on T32AI187320.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award